CF
BCAX

Cantor Fitzgerald’s Bicara Therapeutics BCAX Stock Holding History

Cantor Fitzgerald’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,000
Closed -$1.58M – 402
2025
Q3 		$1.58M Buy
+100,000
New +$1.12M 0.02% 174

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $173M AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Cantor Fitzgerald's BCAX Position: Q4 2025 in Review

Cantor Fitzgerald sold out of Bicara Therapeutics (BCAX) in Q4 2025, closing a stake of 100,000 shares — an estimated $1.58M sold.

Cantor Fitzgerald first reported a position in BCAX in Q3 2025 and held it in 1 quarter. The position peaked at $1.58M in Q3 2025. 141 funds tracked by Wall St. Rank hold BCAX as of Q4 2025.

  • Cantor Fitzgerald reported no remaining Bicara Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 100,000 Bicara Therapeutics shares in Q4 2025, an estimated $1.58M.
  • Cantor Fitzgerald first reported a position in Bicara Therapeutics in Q3 2025 and held it in 1 quarter.
  • Cantor Fitzgerald's Bicara Therapeutics position peaked at $1.58M in Q3 2025.
  • 141 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q4 2025.

Based on Cantor Fitzgerald's 13F filing for Q4 2025, filed 17 Feb 2026.